PRGO

Perrigo Company plc (PRGO) - 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 27, 2026. Perrigo is a leading pure-play self-care company operating globally, primarily in North America and Europe. The company recently reorganized its reporting segments into Self Care, Specialty Care, and Infant Formula, with other categories (including the recently divested Dermacosmetics Business) reported as "All Other." The company is currently led by Interim CEO Albert A. Manzone following the resignation of Patrick Lockwood-Taylor in June 2026.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 3.2% ($33.5 million) in Q2 and 5.2% ($108.2 million) in the first half of 2026 compared to the prior year. This was driven by soft consumption, lower retailer inventory levels in the Self Care segment, and the divestiture of the Dermacosmetics Business.
• Goodwill Impairment: A significant non-cash goodwill impairment charge of $330.8 million was recorded in the first half of 2026. This resulted from a segment reorganization that reallocated goodwill to new reporting units (Women's Health, Infant Formula, and Oral Care), where carrying values exceeded fair values.
• Divestiture Gain: The sale of the Dermacosmetics Business on April 30, 2026, generated a pre-tax gain of $129.5 million, which significantly boosted Q2 net income despite operating losses.
• Restructuring Costs: Restructuring charges increased to $89.5 million for the six months ended June 27, 2026, primarily due to the "Operational Enhancement Program" and "Nutrition Network Optimization."
• Operating Loss: The six-month operating loss of $348.9 million contrasts sharply with the $92.3 million operating income in the prior year period, largely due to the impairment charge and lower gross profit.

Guidance, Outlook, and Risks

• Strategic Review: The company announced a strategic review of its Infant Formula business to assess alternatives, accelerate cash flows, and optimize portfolio impact. This follows a partial plant shutdown in Vermont to rationalize capacity.
• Operational Enhancement: A new two-year program aims to reduce approximately 7% of the workforce and achieve $80–$100 million in annual pre-tax cost savings, with cash costs of $80–$90 million expected primarily in 2026.
• Legal Contingencies: Significant litigation risks remain, including price-fixing lawsuits related to the former Rx business (with a $67.0 million accrual), talcum powder product liability claims (~220 pending lawsuits), and ongoing IRS tax disputes regarding transfer pricing and omeprazole sales.
• Market Risks: The company faces exposure to geopolitical conflicts (Ukraine, Middle East), inflationary pressures, supply chain disruptions, and foreign currency fluctuations. Tariff uncertainties and potential refunds on previously paid duties are also monitored.
• Goodwill Sensitivity: Management notes that the Women's Health and Skin Health reporting units have passing margins of less than 10% in impairment testing, making them sensitive to changes in discount rates or market capitalization.

Investor Verification Checklist

• Impairment Details: Verify the specific assumptions used in the goodwill impairment test for the Women's Health, Infant Formula, and Oral Care units, particularly given the low passing margins.
• Divestiture Proceeds: Confirm the timing and amount of the contingent consideration ($18.0 million remaining) from the Dermacosmetics Business sale.
• Infant Formula Strategy: Monitor the outcome of the strategic review for the Infant Formula segment and the impact of the Vermont plant shutdown on future capacity and costs.
• Litigation Exposure: Review the status of the price-fixing MDL bellwether trials (scheduled for 2027-2028) and the potential for increased accruals beyond the current $91.9 million total litigation reserve.
• Tax Disputes: Track the appeal of the IRS refund litigation regarding omeprazole transfer pricing, which could impact future tax liabilities by $25.0–$128.0 million if the current position is not sustained.
• Debt Covenants: Ensure continued compliance with the 3.00:1.00 net leverage ratio and 3.00:1.00 interest coverage ratio covenants under the Senior Secured Credit Facilities.